Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.

Autor:	Underwood B; Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA., Zhao Q; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA., Walker AR; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Mims AS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Vasu S; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Long M; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Z Haque T; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Blaser BW; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Grieselhuber NR; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Wall SA; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Behbehani GK; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Blachly JS; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Larkin K; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Byrd JC; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Garzon R; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Wang TF; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA., Bhatnagar B; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.; The Ohio State University Comprehensive Cancer Center, Columbus OH 43210, USA.
Jazyk:	angličtina
Zdroj:	International journal of hematologic oncology [Int J Hematol Oncol] 2020 Sep 04; Vol. 9 (3), pp. IJH28. Date of Electronic Publication: 2020 Sep 04.
DOI:	10.2217/ijh-2020-0009
Abstrakt:	Aim: There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase. Materials & Methods: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed. Results: 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender. Conclusion: These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase. Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. (© 2020 Bhavana Bhatnagar.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu